1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Mabwell (Shanghai) Bioscience Co., Ltd.

Mabwell (Shanghai) Bioscience Co., Ltd.

688062.SS
Mabwell (Shanghai) Bioscience Co., Ltd.CN flagShanghai Stock Exchange
32.41
CNY
-1.47
- -
12.95BMarket Cap

Total Valuation

Mabwell (Shanghai) Bioscience Co., Ltd. carries a market capitalization of 12.95B, placing it among publicly traded companies globally. Its enterprise value stands at 12.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap12.95B
Enterprise Value12.42B

Share Statistics

Mabwell (Shanghai) Bioscience Co., Ltd. currently has 399.60M shares outstanding.

Shares Outstanding399.60M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 60.95, and the price-to-book ratio stands at -2.28.

PE RatioN/A
PS Ratio60.95
PB Ratio-2.28
P/TBV Ratio15.36
P/FCF Ratio45.29
P/OCF RatioN/A

Enterprise Valuation

EV / Sales66.99
EV / EBITDAN/A
EV / EBITN/A
EV / FCF38.73

Financial Position

Mabwell (Shanghai) Bioscience Co., Ltd. maintains a current ratio of 0.90, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 231.76, indicating elevated leverage, while an interest coverage ratio of -15.14 demonstrates limited ability to service its debt obligations.

Current Ratio0.90
Quick Ratio0.67
Debt / Equity231.76
Debt / EBITDA-2.15
Interest Coverage-15.14

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-25.48
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover0.23

Taxes

Income Tax-2.76M
Effective Tax RateN/A

Stock Price Statistics

Mabwell (Shanghai) Bioscience Co., Ltd.'s stock has gained approximately 4.48098% over the past 52 weeks. The 50-day moving average sits at 31.21, while the 200-day moving average is 37.87.

Beta (5Y)N/A
52-Week Price Change4.48098%
50-Day Moving Average31.21
200-Day Moving Average37.87
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Mabwell (Shanghai) Bioscience Co., Ltd. generated 185.42M in revenue and converted that into -1.15B in net income, yielding earnings per share of -2.88. EBITDA reached -1.08B, while operating income came in at -1.08B.

Revenue185.42M
Gross Profit141.09M
Operating Income-1.08B
Pretax Income-1.16B
Net Income-1.15B
EBITDA-1.08B
EBIT-1.08B
Earnings Per Share (EPS)-2.88

Balance Sheet

Mabwell (Shanghai) Bioscience Co., Ltd. holds 1.39B in cash and equivalents against 2.33B in total debt, resulting in a net debt position of 579.10M. Total book value stands at -4.95B, with working capital of -203.15M providing operational flexibility.

Cash & Cash Equivalents1.39B
Total Debt2.33B
Net Debt579.10M
Equity (Book Value)-4.95B
Book Value Per Share-12.38
Working Capital-203.15M

Cash Flow

After subtracting -249.52M in capital expenditures, free cash flow totaled -249.52M - equivalent to -0.62 per share.

Operating Cash FlowN/A
Capital Expenditures-249.52M
Free Cash Flow-249.52M
FCF Per Share-0.62

Margins

Mabwell (Shanghai) Bioscience Co., Ltd. operates with a gross margin of 76.09, reflecting its pricing power and cost economics. The operating margin of -582.44 and net profit margin of -620.35 provide insight into operational efficiency.

Gross Margin76.09
Operating Margin-582.44
Pretax Margin-623.08
Profit Margin-620.35
EBITDA Margin-582.44

Dividends & Yields

The company's payout ratio of -6.66 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share0.19
Dividend YieldN/A
Payout Ratio-6.66
Shareholder Yield-3.81
FCF Yield2.21

Scores

Mabwell (Shanghai) Bioscience Co., Ltd. posts an Altman Z-Score of -0.69, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-0.69